Humanity shouldn`t expect a single “magic pill” for health and longevity. Instead, a comprehensive “magic kit” for well-being is projected to emerge within the next decade. This forecast comes from Vladimir Mitkevich, Deputy Director for Scientific Work at the Engelhardt Institute of Molecular Biology of the Russian Academy of Sciences. Mitkevich shared his insights during a Moscow-Belgorod video conference themed “New Materials for Quality of Life: Scientific Developments for Technological Leadership.”
A video conference discussing “New Materials for Quality of Life: Scientific Developments for Technological Leadership.”
According to Mitkevich, this kit will feature between 10 to 20 innovative medical compounds along with a holistic set of measures. These measures will draw not only from modern pharmacology but also from human psychology, all geared towards promoting healthy and extended lifespans.
“Everyone desires not just to prolong life, but to ensure it remains fulfilling,” the scientist emphasized. He highlighted that continuous stimulation of brain activity is crucial, as optimal brain function drives other bodily processes and serves as a preventive measure against many diseases.
Vladimir Mitkevich, Deputy Director for Scientific Work at the Engelhardt Institute of Molecular Biology of the Russian Academy of Sciences.
In a related discussion, Roman Solovyov, Development Director at Biotehno company, referenced a recent conversation between Russian President Vladimir Putin and Chinese President Xi Jinping. During this discussion, the leaders explored the prospects of achieving biological immortality. Solovyov added, “Biotechnology is the science of the future; it`s a trend that will advance and allow us to extend and enhance the quality of human life.”
Roman Solovyov, Development Director at Biotehno company.
The Rigorous Path for New Drugs
Participants in the video conference also addressed Russia`s ambition for pharmaceutical self-sufficiency. Alexander Obukhov, Medical Department Director at Pharmstandard JSC, recalled, “We remember when international companies ceased supplying us with insulin due to conflicts. This disruption occurred very quickly, but now our country has established a complete production cycle for insulin.”
He acknowledged, however, that the journey for a new drug to reach human use often spans many years. “Every molecule discovered by scientists comes with a presumption of guilt. All our research is dedicated to rigorously proving that this compound is both safe and effective,” Obukhov explained.
This stringent process also applies to the development of treatments for orphan (rare) diseases. Obukhov reported that preclinical trials are currently in progress with scientists from Belgorod State University (BelSU) for a drug aimed at Von Willebrand disease—a rare inherited blood clotting disorder caused by a genetic defect involving abnormal protein production.
He underscored the vital role of the Belgorod vivarium in this research. Specifically, he noted that the drug`s pharmacological safety is being assessed on dogs, its intravenous toxicity on rats, and its pyrogenicity on rabbits.
Obukhov expressed confidence that scientists would soon achieve positive results, enabling Russia to produce its own effective treatment for this rare condition.
Alzheimer`s Disease: An Ongoing Scientific Challenge
Developing a treatment for Alzheimer`s disease represents another critical area of focus for various Russian scientific teams.
“We are actively working to unravel the mechanisms behind Alzheimer`s disease, which is the most prevalent aging-related pathology. There has been a long-standing debate about the primary driving mechanism of Alzheimer`s, and a detailed understanding still eludes us. However, recent research strongly suggests that beta-amyloid plays a central role in this disease,” stated Vladimir Mitkevich.
He further elaborated, “For quite some time, we have been investigating why an initially normal physiological molecule, indispensable for the existence of any organism, suddenly transforms into aggregates. These aggregates then trigger neurotoxicity and initiate the pathological cascade characteristic of Alzheimer`s disease.”
Rupert Blackwood 
Clement Ashworth